Skip to main content
Erschienen in: Current Gastroenterology Reports 2/2010

01.04.2010

Sphincter of Oddi Dysfunction

verfasst von: John Baillie

Erschienen in: Current Gastroenterology Reports | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Sphincter of Oddi dysfunction (SOD) is a poorly-understood disorder, typically presenting as postcholecystectomy, “biliary-type,” right-sided abdominal and/or chest wall pain. Most patients referred to specialist clinics for work-up of presumed SOD do not, in fact, have anything wrong with their bile ducts or biliary sphincter mechanisms. A careful history and focused physical examination will often identify the true source of the pain syndrome, ranging from chest wall costochondritis and nerve injury at surgical trochar sites, to gastroparesis and visceral hypersensitivity (“irritable bowel”). The Rome III classification of functional gallbladder and biliary disorders defines SOD as episodic (not daily) pain lasting more than 30 min, which is disruptive of normal activities and not associated with bowel upset. It is not relieved by gastric acid suppression or antispasmodics. Other causes of abdominal pain must be excluded. Standard work-up includes endoscopic retrograde cholangiopancreatography (ERCP) with biliary manometry, which risks post-ERCP pancreatitis, especially in young women with normal bile ducts and liver serology. Noninvasive tests for SOD, such as timed (“gated”) cholecystokinin (CCK)-stimulated hepatobiliary iminodiacetic acid (HIDA) scans and secretin-stimulated magnetic resonance cholangiopancreatography, are imperfect and still evolving. Although many doubt the very existence of SOD, a multidisciplinary approach to the management of pre- and postcholecystectomy abdominal pain syndromes is long overdue.
Literatur
1.
Zurück zum Zitat Geenen JE, Hogan WJ, Dodds WJ, et al.: The efficacy of endoscopic sphincterotomy after cholecystectomy in patients with sphincter-of-Oddi dysfunction. N Engl J Med 1989, 320:82–87.PubMedCrossRef Geenen JE, Hogan WJ, Dodds WJ, et al.: The efficacy of endoscopic sphincterotomy after cholecystectomy in patients with sphincter-of-Oddi dysfunction. N Engl J Med 1989, 320:82–87.PubMedCrossRef
2.
Zurück zum Zitat Toouli J: Sphincter of Oddi: function, dysfunction, and its management. J Gastroenterol Hepatol 2009, 24(Suppl 3):S57–S62.CrossRefPubMed Toouli J: Sphincter of Oddi: function, dysfunction, and its management. J Gastroenterol Hepatol 2009, 24(Suppl 3):S57–S62.CrossRefPubMed
3.
Zurück zum Zitat Behar J, Corazziari E, Guelrud M, et al.: Functional gallbladder and sphincter of Oddi disorders. Gastroenterology 2006, 130:1498–1509.CrossRefPubMed Behar J, Corazziari E, Guelrud M, et al.: Functional gallbladder and sphincter of Oddi disorders. Gastroenterology 2006, 130:1498–1509.CrossRefPubMed
5.
Zurück zum Zitat Ruffolo TA, Sherman S, Lehman, et al.: Gallbladder ejection fraction and its relationship to sphincter of Oddi dysfunction. Dig Dis Sci 1994, 39:289–292. Ruffolo TA, Sherman S, Lehman, et al.: Gallbladder ejection fraction and its relationship to sphincter of Oddi dysfunction. Dig Dis Sci 1994, 39:289–292.
6.
Zurück zum Zitat Choudhry U, Ruffolo T, Jamidar P, et al.: Sphincter of Oddi dysfunction in patients with intact gallbladder: therapeutic response to endoscopic sphincterotomy. Gastrointest Endosc 1993; 39:492–495.CrossRefPubMed Choudhry U, Ruffolo T, Jamidar P, et al.: Sphincter of Oddi dysfunction in patients with intact gallbladder: therapeutic response to endoscopic sphincterotomy. Gastrointest Endosc 1993; 39:492–495.CrossRefPubMed
7.
Zurück zum Zitat Freeman ML, Guda NM: Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc 2004, 59:845–864.CrossRefPubMed Freeman ML, Guda NM: Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc 2004, 59:845–864.CrossRefPubMed
8.
Zurück zum Zitat Freeman ML: Post-ERCP pancreatitis: patient and technique-related risk factors. JOP 2002, 3:169–176.PubMed Freeman ML: Post-ERCP pancreatitis: patient and technique-related risk factors. JOP 2002, 3:169–176.PubMed
9.
Zurück zum Zitat Saad AM, Fogel EL, McHenry L, et al.: Pancreatic duct stent placement prevents post-ERCP pancreatitis in patients with suspected sphincter of Oddi dysfunction but normal manometry results. Gastrointest Endosc 2008, 67:255–261.CrossRefPubMed Saad AM, Fogel EL, McHenry L, et al.: Pancreatic duct stent placement prevents post-ERCP pancreatitis in patients with suspected sphincter of Oddi dysfunction but normal manometry results. Gastrointest Endosc 2008, 67:255–261.CrossRefPubMed
10.
Zurück zum Zitat • Freeman ML: Pancreatic stents for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Clin Gastroenterol Hepatol 2007, 5:1354–1365. This article describes the role of pancreatic stents in the prevention of post-ERCP pancreatitis, as discussed by the pioneer in the field. • Freeman ML: Pancreatic stents for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Clin Gastroenterol Hepatol 2007, 5:1354–1365. This article describes the role of pancreatic stents in the prevention of post-ERCP pancreatitis, as discussed by the pioneer in the field.
11.
Zurück zum Zitat Senol A, Saritas U, Demirkan H: Efficacy of intramuscular diclofenac and fluid replacement in prevention of post-ERCP pancreatitis. World J Gastroenterol 2009, 15:3999–4004.CrossRefPubMed Senol A, Saritas U, Demirkan H: Efficacy of intramuscular diclofenac and fluid replacement in prevention of post-ERCP pancreatitis. World J Gastroenterol 2009, 15:3999–4004.CrossRefPubMed
12.
Zurück zum Zitat • Elmunzer BJ, Waljee AK, Elta GH, et al.: A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. Gut 2008, 57:1262–1267. This article presents a meta-analysis of four prospective studies appearing to show that NSAIDs may significantly reduce the risk of post-ERCP pancreatitis. • Elmunzer BJ, Waljee AK, Elta GH, et al.: A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. Gut 2008, 57:1262–1267. This article presents a meta-analysis of four prospective studies appearing to show that NSAIDs may significantly reduce the risk of post-ERCP pancreatitis.
13.
Zurück zum Zitat Staritz M, Poralla T, Dormeyer HH, et al.: Endoscopic removal of common bile duct stones through the intact papilla after medical sphincter dilation. Gastroenterology 1985, 88:1807–1811.PubMed Staritz M, Poralla T, Dormeyer HH, et al.: Endoscopic removal of common bile duct stones through the intact papilla after medical sphincter dilation. Gastroenterology 1985, 88:1807–1811.PubMed
14.
Zurück zum Zitat Madácsy L, Kurucsai G, Fejes R, et al, Prophylactic pancreas stenting followed by needle-knife fistulotomy in patients with sphincter of Oddi dysfunction and difficult cannulation: new method to prevent post-ERCP pancreatitis. Dig Endosc 2009, 21:8–13.CrossRefPubMed Madácsy L, Kurucsai G, Fejes R, et al, Prophylactic pancreas stenting followed by needle-knife fistulotomy in patients with sphincter of Oddi dysfunction and difficult cannulation: new method to prevent post-ERCP pancreatitis. Dig Endosc 2009, 21:8–13.CrossRefPubMed
15.
Zurück zum Zitat Freeman ML: Pancreatic stents for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Clin Gastroenterol Hepatol 2007, 5:1354–1365.CrossRefPubMed Freeman ML: Pancreatic stents for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Clin Gastroenterol Hepatol 2007, 5:1354–1365.CrossRefPubMed
16.
Zurück zum Zitat Cheon YK, Cho YD, Moon JH, et al.: Effects of vardenafil, a phosphodiesterase type-5 inhibitor, on sphincter of Oddi motility in patients with suspected biliary sphincter of Oddi dysfunction. Gastrointest Endosc 2009, 69:1111–1116.CrossRefPubMed Cheon YK, Cho YD, Moon JH, et al.: Effects of vardenafil, a phosphodiesterase type-5 inhibitor, on sphincter of Oddi motility in patients with suspected biliary sphincter of Oddi dysfunction. Gastrointest Endosc 2009, 69:1111–1116.CrossRefPubMed
17.
Zurück zum Zitat Affronti J: Levitra for sphincter of Oddi dysfunction? Are you kidding? Gastrointest Endosc 2009, 69:1117–1119.CrossRefPubMed Affronti J: Levitra for sphincter of Oddi dysfunction? Are you kidding? Gastrointest Endosc 2009, 69:1117–1119.CrossRefPubMed
18.
Zurück zum Zitat Khashab MA, Watkins JL, McHenry Jr L, et al.: Frequency of sphincter of Oddi dysfunction in patients with previously normal sphincter of Oddi manometry studies. Endoscopy 2009 (Epub ahead of print). Khashab MA, Watkins JL, McHenry Jr L, et al.: Frequency of sphincter of Oddi dysfunction in patients with previously normal sphincter of Oddi manometry studies. Endoscopy 2009 (Epub ahead of print).
19.
Zurück zum Zitat Draganov PV, Kowalczyk L, Forsmark CE: Prospective trial comparing solid-state catheter and water-perfusion triple-lumen catheter for sphincter of Oddi manometry done at the time of ERCP. Gastrointest Endosc 2009, 70:92–95.CrossRefPubMed Draganov PV, Kowalczyk L, Forsmark CE: Prospective trial comparing solid-state catheter and water-perfusion triple-lumen catheter for sphincter of Oddi manometry done at the time of ERCP. Gastrointest Endosc 2009, 70:92–95.CrossRefPubMed
20.
Zurück zum Zitat Aisen AM, Sherman S, Jennings SG, et al.: Comparison of secretin-stimulated magnetic resonance pancreatography and manometry results in patients with suspected sphincter of Oddi dysfunction. Acad Radiol 2008, 15:601–609.CrossRefPubMed Aisen AM, Sherman S, Jennings SG, et al.: Comparison of secretin-stimulated magnetic resonance pancreatography and manometry results in patients with suspected sphincter of Oddi dysfunction. Acad Radiol 2008, 15:601–609.CrossRefPubMed
21.
Zurück zum Zitat Baillie J, Kimberly J: Prospective comparison of secretin-stimulated MRCP with manometry in the diagnosis of sphincter of Oddi dysfunction types II and III. Gut 2007, 56:742–744.CrossRefPubMed Baillie J, Kimberly J: Prospective comparison of secretin-stimulated MRCP with manometry in the diagnosis of sphincter of Oddi dysfunction types II and III. Gut 2007, 56:742–744.CrossRefPubMed
22.
Zurück zum Zitat Elmi F, Silverman WB: biliary sphincter of Oddi dysfunction type I versus occult biliary microlithiasis in post-cholecystectomy patients: are they both part of the same clinical entity? Dig Dis Sci 2009 (Epub ahead of print). Elmi F, Silverman WB: biliary sphincter of Oddi dysfunction type I versus occult biliary microlithiasis in post-cholecystectomy patients: are they both part of the same clinical entity? Dig Dis Sci 2009 (Epub ahead of print).
24.
Zurück zum Zitat Cohen S, Bacon B, Berlin JA, et al.: National Institutes of Health State-of-the-Science Conference Statement: ERCP for diagnosis and therapy, January 14–16, 2002. Gastrointest Endosc 2002, 56:803–809.CrossRefPubMed Cohen S, Bacon B, Berlin JA, et al.: National Institutes of Health State-of-the-Science Conference Statement: ERCP for diagnosis and therapy, January 14–16, 2002. Gastrointest Endosc 2002, 56:803–809.CrossRefPubMed
Metadaten
Titel
Sphincter of Oddi Dysfunction
verfasst von
John Baillie
Publikationsdatum
01.04.2010
Verlag
Current Science Inc.
Erschienen in
Current Gastroenterology Reports / Ausgabe 2/2010
Print ISSN: 1522-8037
Elektronische ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-010-0096-1

Weitere Artikel der Ausgabe 2/2010

Current Gastroenterology Reports 2/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.